NASDAQ:CERE Cerevel Therapeutics (CERE) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$44.96▼$44.9650-Day Range$40.30▼$44.9652-Week Range$19.59▼$44.99VolumeN/AAverage Volume1.71 million shsMarket Capitalization$8.19 billionP/E RatioN/ADividend YieldN/APrice Target$44.13 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get Cerevel Therapeutics alerts: Email Address Cerevel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.13 Rating ScoreUpside/Downside1.9% Downside$44.13 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$1.03 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.59) to ($2.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.03 out of 5 starsMedical Sector923rd out of 927 stocksPharmaceutical Preparations Industry424th out of 425 stocks 1.1 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageCerevel Therapeutics has received no research coverage in the past 90 days.Read more about Cerevel Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CERE. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Cerevel Therapeutics this week, compared to 4 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,029,500.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders.Percentage Held by Institutions87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerevel Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.59) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -16.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -16.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 12.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold.Click here to review my research and unique strategy to score potential profits from this under-the- About Cerevel Therapeutics Stock (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More Ad Crypto 101 MediaThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold.Click here to review my research and unique strategy to score potential profits from this under-the- CERE Stock News HeadlinesSeptember 16 at 4:44 AM | msn.comEli Lilly and AbbVie: J.P. Morgan Selects the Top Large-Cap Pharma Stocks to BuySeptember 10, 2024 | finance.yahoo.comBain closes $3B biotech fund amid flurry of startup buyoutsSeptember 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 27, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Global Wireless Brain Sensors Market to Accelerate Substantially at a CAGR of ~9% by 2030 | DelveInsightAugust 14, 2024 | msn.comAnalyst revises AbbieVie stock price target on drug-sale estimatesAugust 6, 2024 | ca.finance.yahoo.comABBV Sep 2024 200.000 callAugust 5, 2024 | ca.finance.yahoo.comABBV Aug 2024 245.000 callAugust 4, 2024 | uk.finance.yahoo.comABBV Aug 2024 187.500 putSeptember 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 3, 2024 | uk.finance.yahoo.comABBV Aug 2024 160.000 callAugust 1, 2024 | markets.businessinsider.comAbbVie Completes Acquisition Of Cerevel; Reaffirms Full-year Adj. EPS Guidance RangeAugust 1, 2024 | prnewswire.comAbbVie Completes Acquisition of Cerevel TherapeuticsAugust 1, 2024 | finance.yahoo.comCerevel Therapeutics Holdings Inc (673.MU)July 26, 2024 | ca.finance.yahoo.comIMGN Dec 2025 10.000 putJuly 26, 2024 | bizjournals.comAfter FTC involvement, here’s when AbbVie-Cerevel deal could closeJuly 25, 2024 | benzinga.comCheck Out What Whales Are Doing With CEREJuly 25, 2024 | msn.comCerevel ticks higher as AbbVie says it expects deal to close soonJuly 22, 2024 | msn.comCerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVieSee More Headlines Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$44.13 High Stock Price Target$45.00 Low Stock Price Target$38.00 Potential Upside/Downside-1.9%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-432,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-98.94% Return on Assets-45.07% Debt Debt-to-Equity Ratio0.60 Current Ratio10.22 Quick Ratio10.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.71 per share Price / Book12.12Miscellaneous Outstanding Shares182,200,000Free Float172,903,000Market Cap$8.19 billion OptionableOptionable Beta1.40 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. N. Anthony Coles Jr. (Age 64)M.P.H., Executive Chairman Comp: $1.14MMr. Mark Bodenrader (Age 51)VP of Finance & Chief Accounting Officer Comp: $496.17kDr. John J. Renger Ph.D. (Age 55)Chief Scientific Officer Comp: $779.75kDr. Ramiro Sanchez M.D. (Age 63)Chief Medical Officer Comp: $805.13kMr. Ronald C. Renaud Jr. (Age 55)M.B.A., President, CEO & Director Dr. Susan Altschuller M.B.A. (Age 42)Ph.D., Chief Financial Officer Mr. Matthew CalistriVice President of Investor RelationsMr. Scott M. Akamine J.D. (Age 39)Chief Legal Officer & Corporate Secretary Comp: $444.74kMr. Kenneth A. DiPietro (Age 65)Chief Human Resources Officer Ms. Kathleen Tregoning M.A. (Age 53)Chief Corporate Affairs Officer Comp: $600.79kMore ExecutivesKey CompetitorsCNX ResourcesNYSE:CNXWarrior Met CoalNYSE:HCCArch ResourcesNYSE:ARCHHallador EnergyNASDAQ:HNRGTeva Pharmaceutical IndustriesNYSE:TEVAView All CompetitorsInsiders & InstitutionsWater Island Capital LLCSold 21,937 shares on 8/16/2024Ownership: 0.421%Susquehanna International Group LLPBought 215,800 shares on 8/16/2024Ownership: 0.000%Murchinson Ltd.Bought 100,000 shares on 8/16/2024Ownership: 0.055%Algert Global LLCBought 7,312 shares on 8/16/2024Ownership: 0.022%Dark Forest Capital Management LPSold 21,077 shares on 8/15/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions CERE Stock Analysis - Frequently Asked Questions How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) released its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.61) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.02. Who are Cerevel Therapeutics' major shareholders? Cerevel Therapeutics' top institutional shareholders include Avoro Capital Advisors LLC (4.14%), Alpine Associates Management Inc. (1.29%), Marshall Wace LLP (1.03%) and Farallon Capital Management LLC (0.65%). Insiders that own company stock include Bain Capital Investors Llc, Perceptive Advisors Llc, Ronald C Renaud Jr, N Anthony Coles, Kenneth Dipietro, Paul D Burgess, Mark Bodenrader, Susan Altschuller, Ramiro Sanchez, John Renger, Scott Akamine, Abraham Ceesay and Deval L Patrick. View institutional ownership trends. What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO) and Hess (HES). This page (NASDAQ:CERE) was last updated on 9/16/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerevel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERE Stock Alerts